The Olivia Newton-John Cancer Wellness & Research Centre (ONJ Centre) has been accredited for both oncology and haematology Phase 1 studies.
A Phase 1 study is the initial stage of a clinical trial where a new treatment is first trialed in a small group of people to evaluate its safety, determine a safe dosage range, and identify side effects. Early indications of anti-cancer benefits can also be seen in such trials.
By qualifying as an accredited site for such trials, the ONJ Centre will be able to run trials that involve the newest Novartis treatments for both solid tumours and cancers of the blood from the Novartis early drug pipeline. This qualification for escalation and expansion of early phase studies will increase access to new drugs for patients of the ONJ Centre.
“The ONJ Centre is already a leading Cancer Centre in Australia with over 200 ongoing clinical trials. This partnership will further advance our engagement in the development and application of breakthrough research for the benefit of patients,” said Director of Clinical Trials at Austin Health and Senior Clinical Research Fellow, A/Prof Hui Gan.
Receiving accreditation for a major global pharmaceutical company is a strong endorsement of the quality of patient care and clinical research that is undertaken at the ONJ Centre.
Access to all clinical trials depends on patient eligibility. Individuals seeking to join a clinical trial at the ONJ Centre must first be referred by their doctor or specialist
Access to all clinical trials depends on patient eligibility. Individuals seeking to join a clinical trial at the ONJ Centre must first be referred by their doctor or specialist.
Clinical trials are listed at https://www.cancervic.org.au/trials/. For cancer clinical trials at the ONJ Centre search by hospital, Austin Health.